# Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

> **NCT02118610** · NA · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 63 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** L-tetrahydropalmatine (30mg)
- **DRUG:** Sugar pill

## Key facts

- **NCT ID:** NCT02118610
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2018-12
- **Final completion:** 2019-06
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118610, "Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02118610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*